Back to top
more

BellRing Brands (BRBR)

(Delayed Data from NYSE)

$49.67 USD

49.67
1,540,553

-1.56 (-3.05%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $49.64 -0.03 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Envista (NVST) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of 6.82% and 0.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BellRing Brands (BRBR) Reports Next Week: What Awaits?

by Zacks Equity Research

BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abbott (ABT) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of 17.69% and 7.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BellRing Brands (BRBR) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

BellRing Brands (BRBR) delivered earnings and revenue surprises of 8.70% and 1.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Q2 Earnings Meet Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of 0% and 3.92%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BellRing Brands (BRBR) Reports Next Week: What Awaits?

by Zacks Equity Research

BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are These Medical Stocks Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BellRing Brands (BRBR) Loses 11.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

BellRing Brands (BRBR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

LabCorp (LH) to Expand Nonclinical Development With New Buyout

by Zacks Equity Research

LabCorp's (LH) acquisition of Toxikon can expand its full-service drug development and medical device solutions portfolio.

BellRing Brands (BRBR) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

BellRing Brands (BRBR) delivered earnings and revenue surprises of -7.41% and 5.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Masimo (MASI) Reports SedLine's Psi & DSA Parameter Findings

by Zacks Equity Research

The study findings show that monitoring with Masimo (MASI) SedLine Brain Function Monitoring parameters during CEA surgery can reduce the risk of postoperative delirium.

Intuit (INTU) Readies to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Intuit (INTU) Q1 results are likely to reflect benefits from strong momentum in the online ecosystem, solid demand for tax products and revenue contribution from the Credit Karma business.

Should You Buy BellRing Brands (BRBR) Ahead of Earnings?

by Zacks Equity Research

BellRing Brands (BRBR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NVIDIA (NVDA) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

NVIDIA's (NVDA) Q3 performance is likely to have benefited from strong demand for chips used in gaming consoles and data centers amid the work-and-learn-at-home and gaming waves.

Coupang (CPNG) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Coupang's (CPNG) third-quarter results are expected to reflect strength in its e-commerce business and momentum across Rocket fresh and Coupang eats.

Upstart (UPST) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Upstart's (UPST) third-quarter results are expected to reflect benefits from strong AI efforts and solid momentum across its platform.

ContextLogic (WISH) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

ContextLogic's (WISH) third-quarter results are likely to reflect gains from strength in ProductBoost and Logistics businesses.

fuboTV (FUBO) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

fuboTV's (FUBO) third-quarter results are expected to reflect strength across sports streaming offerings and solid online sports wagering momentum.

Fiverr (FVRR) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Fiverr's (FVRR) third-quarter 2021 results are expected to reflect gains from its international expansion, marketing efficiency and technology enhancements.

Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Is BellRing Brands (BRBR) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

What's in the Cards for Doximity (DOCS) in Q2 Earnings?

by Zacks Equity Research

Doximity's (DOCS) products like Doximity Dialer and Residency Navigator have been in focus and we expect both to have generated significant revenues during the fiscal second quarter.

Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in the Pharmaceutical segment.

Fulgent Genetics (FLGT) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

The recent buyout of CSI Laboratories and strategic investments in early cancer screening are likely to have contributed to growth for Fulgent Genetics (FLGT).

What's in Store for Canopy Growth (CGC) in Q2 Earnings?

by Zacks Equity Research

Canopy Growth's (CGC) newly-added Ace Valley and Supreme Cannabis hold part of the company's market share in fiscal Q2.